Jill Buck

1.8k total citations
15 papers, 133 citations indexed

About

Jill Buck is a scholar working on Oncology, Biotechnology and Genetics. According to data from OpenAlex, Jill Buck has authored 15 papers receiving a total of 133 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Biotechnology and 6 papers in Genetics. Recurrent topics in Jill Buck's work include Cancer Research and Treatments (9 papers), CAR-T cell therapy research (8 papers) and Virus-based gene therapy research (6 papers). Jill Buck is often cited by papers focused on Cancer Research and Treatments (9 papers), CAR-T cell therapy research (8 papers) and Virus-based gene therapy research (6 papers). Jill Buck collaborates with scholars based in United States, India and Canada. Jill Buck's co-authors include Gary A. Adams, E. Antonio Chiocca, John Barrett, Nathan Demars, Laurence J.N. Cooper, Robert G. Maki, Nira Hadar, John S. Yu, Sant P. Chawla and Yunxia Wang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neuro-Oncology.

In The Last Decade

Jill Buck

13 papers receiving 127 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jill Buck United States	5	47	42	34	23	22	15	133
Krystyna Adamska Poland	8	64 1.4×	8 0.2×	26 0.8×	4 0.2×	23 1.0×	27	173
Kate Gilbert United Kingdom	8	11 0.2×	18 0.4×	4 0.1×	16 0.7×	10 0.5×	23	158
Deborah Levenson United States	7	107 2.3×	30 0.7×	11 0.3×	7 0.3×		74	265
Rebecca Adami Sweden	11	98 2.1×	40 1.0×	5 0.1×	14 0.6×	2 0.1×	36	274
Samuel Walker United States	8	126 2.7×	44 1.0×	46 1.4×	3 0.1×		15	382
Michelle Nayahamui Rooney Australia	7	21 0.4×	4 0.1×	101 3.0×	4 0.2×	5 0.2×	18	313
Thomas J. Curry United States	7	88 1.9×	79 1.9×	7 0.2×	2 0.1×	2 0.1×	22	231
Kate Green United Kingdom	8	21 0.4×	7 0.2×	77 2.3×	1 0.0×	3 0.1×	21	289
Thailand Thailand	7	41 0.9×	41 1.0×	4 0.1×	83 3.6×	5 0.2×	22	223

Countries citing papers authored by Jill Buck

Since Specialization

Citations

This map shows the geographic impact of Jill Buck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill Buck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill Buck more than expected).

Fields of papers citing papers by Jill Buck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jill Buck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill Buck. The network helps show where Jill Buck may publish in the future.

Co-authorship network of co-authors of Jill Buck

This figure shows the co-authorship network connecting the top 25 collaborators of Jill Buck. A scholar is included among the top collaborators of Jill Buck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jill Buck. Jill Buck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

McCord, Matthew, Rimas V. Lukas, Christina Amidei, et al.. (2021). Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient. Neuro-Oncology Advances. 3(1). vdab045–vdab045. 6 indexed citations

Lukas, Rimas V., Robert Cavaliere, Joseph Landolfi, et al.. (2021). CTIM-20. FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology. 23(Supplement_6). vi54–vi54. 3 indexed citations

Chiocca, E. Antonio, Rimas V. Lukas, Clark C. Chen, et al.. (2020). Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.. Journal of Clinical Oncology. 38(15_suppl). 2510–2510. 3 indexed citations

Goldman, Stewart, Sabine Mueller, Susan Chi, et al.. (2020). CTIM-27. PHASE I/II STUDY OF CONTROLLED IL-12 AS IMMUNOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology. 22(Supplement_2). ii39–ii39. 1 indexed citations

Lukas, Rimas V., Sylvia C. Kurz, John S. Yu, et al.. (2020). Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone.. Journal of Clinical Oncology. 38(15_suppl). 2564–2564. 1 indexed citations

Chiocca, E. Antonio, Rimas V. Lukas, John S. Yu, et al.. (2020). Final results of controlled IL-12 monotherapy in adults with grade III or IV gliomas.. Journal of Clinical Oncology. 38(15_suppl). 3040–3040. 1 indexed citations

Chiocca, E. Antonio, Rimas V. Lukas, Ganesh Rao, et al.. (2019). Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.. Journal of Clinical Oncology. 37(15_suppl). 2020–2020. 4 indexed citations

Lebel, François, John Barrett, Heather L. McArthur, et al.. (2018). Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients.. Journal of Clinical Oncology. 36(15_suppl). 3038–3038. 3 indexed citations

Chiocca, E. Antonio, Rimas V. Lukas, John S. Yu, et al.. (2018). ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL. Neuro-Oncology. 20(suppl_6). vi3–vi4. 2 indexed citations

10.

Chiocca, E. Antonio, John S. Yu, Rimas V. Lukas, et al.. (2017). ATIM-26. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULT RECURRENT GLIOBLASTOMA. Neuro-Oncology. 19(suppl_6). vi32–vi32. 1 indexed citations

11.

Chiocca, E. Antonio, John S. Yu, Surasak Phuphanich, et al.. (2017). Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.. Journal of Clinical Oncology. 35(15_suppl). 2044–2044. 8 indexed citations

12.

Verschraegen, Claire F., Sant P. Chawla, Chris Ryan, et al.. (2010). A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).. Journal of Clinical Oncology. 28(15_suppl). 10004–10004. 16 indexed citations

13.

Adams, Gary A. & Jill Buck. (2010). Social Stressors and Strain Among Police Officers. Criminal Justice and Behavior. 37(9). 1030–1040. 82 indexed citations

14.

Miller, Wilson H., Izidore S. Lossos, Paul Conkling, et al.. (2009). Darinaparsin a Novel Organic Arsenic Molecule Active in Lymphoma: Development of An Oral Form.. Blood. 114(22). 4759–4759.

15.

Craig, Michael, Sandip Shah, Martin S. Tallman, et al.. (2008). A Phase II Trial of Darinaparsin in Advanced Lymphomas: Report on Safety and Activity.. Blood. 112(11). 1562–1562. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact